(Health Korea News / Changyong Lee) SK Biopharmaceuticals will showcase the digital healthcare platform it is developing to manage the disease of epilepsy patients at the ‘SK AI Summit’ held at COEX until the 5th. This exhibition reflects SK Biopharmaceuticals’ vision to provide innovative value to patients’ disease management using AI and digital technology.
The epilepsy patient management platform being developed by SK Biopharm consists of a mobile app, smartwatch, medical staff web service, and an AI-based seizure prediction system. The mobile app for patients and guardians provides seizure history, seizure statistics, records of seizure triggers, and medication history, and helps patients and guardians effectively prepare for seizures through real-time seizure notification and prediction functions. Smartwatches further enhance patient safety by providing key information such as seizure notifications and predictions in real time.
For medical staff, the web service allows for more systematic patient management by sharing the patient’s seizure history, statistics, and medication information in real time. AI-based EEG analysis is expected to bring about groundbreaking changes in epilepsy management by analyzing and predicting whether epilepsy seizures will occur in real time and immediately notifying patients and guardians, while also delivering meaningful information to medical staff.
The core of digital healthcare is patients’ voluntary data provision and continuous participation. SK Biopharmaceuticals’ epilepsy management platform is expected to have a high user retention rate by implementing the seizure prediction and notification functions that patients consider most important. These features expand opportunities for patients to directly participate and provide data, enabling continuous generation of real world data (RWD).
In particular, through this platform, SK Biopharmaceuticals is expected to be able to secure independent PMS (Post-Marketing Surveillance) data for monitoring the efficacy of not only its drug cenobamate but also other epilepsy drugs.
An official from SK Biopharmaceuticals said, “We plan to support communication about the effects and use experiences of prescribed drugs through a direct communication channel between patients and pharmaceutical companies, and also establish customized patient services and management systems based on this.”
Lee Dong-hoon, CEO of SK Biopharmaceuticals, said, “We expect that we will be able to provide new solutions for patients and medical staff through innovative healthcare services that combine AI and digital technology, and further strengthen our competitiveness in the global digital healthcare market.” “SK Biopharm plans to take the lead in providing a better life for patients through technological advancement,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
